首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

2126418

多發性硬化症診斷市場：策略性洞察與預測（2026-2035 年）

Multiple Sclerosis Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月11日 | 出版商:

Knowledge Sourcing Intelligence | 英文 174 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

多發性硬化症診斷市場預計將從 2026 年的 50.9 億美元成長到 2035 年的 125.8 億美元，複合年成長率為 10.6%。

全球多發性硬化症 (MS) 診斷市場正經歷重大變革，其驅動力在於技術創新以及對疾病早期精準檢測日益成長的重視。該市場涵蓋了廣泛的領域，包括影像系統、臨床實驗室檢測、分子診斷、生物標記檢測和神經系統評估技術。由於單一檢測無法確診該疾病，診斷準確性取決於臨床觀察、磁振造影(MRI)、腦脊髓液 (CSF) 分析、誘發電位檢測以及新興的血液生物標記的綜合分析。隨著醫療機構將早期診斷置於優先地位，以便在發生不可逆的神經損傷之前啟動疾病修正治療，市場需求正在不斷成長。監管機構和神經病學會也在持續更新診斷指南，以反映影像技術、生物標記檢驗以及人工智慧 (AI) 影像解讀等方面的進步，從而改善臨床決策。對精準神經病學、數位診斷和微創生物標記開發的策略性投資，進一步提升了先進診斷技術在全球多發性硬化症診療路徑中的長期重要性。

市場促進因素

多發性硬化症患病率增加

隨著多發性硬化症盛行率的不斷上升，對準確快速的診斷解決方案的需求也日益成長。這是因為早期識別疾病有助於及時啟動疾病修正治療。延遲診斷可能導致發炎活動持續存在，從而造成不可逆的神經損傷。醫療專業人員擴大使用先進的磁振造影系統、腦脊髓液分析和多模態神經系統評估來提高診斷的準確性。這些趨勢正在推動對支持長期疾病管理的綜合診斷技術的需求。

先進磁振造影技術的廣泛應用

磁振造影（MRI）仍然是多發性硬化症診斷的核心技術，因為它能夠顯示腦部和脊髓中的去髓鞘化病變。隨著神經科醫生需要更高的靈敏度來檢測早期發炎變化，對高場強MRI系統和先進成像方案的需求正在增加。由於傳統成像方法在複雜病例中往往無法充分錶徵病變，醫療專業人員擴大採用更高解析度的成像平台。持續的技術創新正在提高診斷準確性，並支援更標準化的神經系統評估。

對早期準確診斷的需求日益成長

早期診斷的重要性日益凸顯，因為在多發性硬化症早期階段啟動疾病修正治療可帶來更大的臨床效益。臨床症狀常與其他神經系統疾病重疊，導致診斷不確定性，延誤治療決策。醫療機構正透過將影像學檢查觀察、生化標記和神經系統檢查整合到綜合評估方案中，來加強多學科診斷流程。這種轉變提高了診斷的準確性，同時也支持為每位患者量身定做個人化治療方案。

擴大血液衍生生物標記開發

對能夠與影像學和腦脊髓液 (CSF) 分析互補的微創診斷工具的需求，推動了血液來源生物標記研究的拓展。傳統的腰椎穿刺仍屬於高侵入性操作，可能會降低患者對診斷評估的接受度。診斷相關企業和學術研究機構正在開發神經絲輕鏈 (NfL) 檢測和其他生物標記技術，以改善疾病監測和臨床評估。生物標記的持續檢驗正在強化精準臨床檢測在多發性硬化症管理中的未來角色。

市場限制因素

先進的磁振造影系統、專業臨床檢測和基於生物標記的診斷方法高成本，阻礙了其在資源匱乏的醫療系統中廣泛應用。由於缺乏單一的確診檢測方法，必須整合多種臨床和實驗室評估，這增加了診斷的複雜性。在一些發展中醫療市場，專業神經病學中心和訓練有素的神經放射科醫生數量有限，可能導致及時診斷的延誤。此外，先進神經影像學和生物標記檢測的報銷政策不盡相同，也會阻礙其在臨床常規應用中的推廣。

按診斷方式
- 磁振造影（MRI）
- 腦脊髓液（CSF）檢查（腰椎穿刺）
- 血液生物標記檢測
- 誘發電位測試
- 光學同調斷層掃描（OCT）
- 其他
透過技術
- 常規磁振造影
- 高場磁振造影（大於3T）
- 人工智慧驅動的醫學影像
- 免疫測量
- 分子診斷
- 其他
最終用戶
- 醫院
- 診斷檢查室
- 神經內科診所
- 學術研究機構

第10章區域分析

北美洲
加拿大
歐洲
德國
中國
日本
印度
拉丁美洲

第11章國別分析

美國
德國
英國
法國
中國
日本
印度
巴西

第12章競爭格局

市佔率分析
競爭環境儀錶板
戰略定位矩陣
產品系列分析
SWOT分析

第13章：公司簡介

Siemens Healthineers AG
GE HealthCare Technologies Inc.
Koninklijke Philips NV
Canon Medical Systems Corporation
F. Hoffmann-La Roche Ltd.
Quest Diagnostics Incorporated
Thermo Fisher Scientific Inc.
Abbott Laboratories
Bio-Rad Laboratories, Inc.
QIAGEN NV
Danaher Corporation
Sysmex Corporation
Fujifilm Holdings Corporation
Illumina, Inc.
Revvity, Inc.

第14章市場預測

市場收益預測
按診斷方式進行的預測
技術預測
最終用戶的預測
區域預測

第15章：投資與成長機遇

新投資領域
人工智慧驅動的診斷解決方案
生物標記創新機遇
策略夥伴關係機會
進入新興市場

第16章：未來市場展望

多發性硬化症（MS）診斷的未來趨勢
下一代生物標記的開發
人工智慧驅動的臨床決策支持
精準神經病學的前景
長期市場機遇

簡介目錄

Product Code: KSI-009129

The Multiple Sclerosis Diagnostics Market is anticipated to grow at a CAGR of 10.6% from USD 5.09 billion in 2026 to USD 12.58 billion in 2035.

The global multiple sclerosis diagnostics market is undergoing a significant transformation driven by technological innovation and a growing emphasis on early and accurate disease detection. This market encompasses a comprehensive range of imaging systems, laboratory assays, molecular diagnostics, biomarker tests, and neurological assessment technologies. Diagnostic accuracy depends upon the integration of clinical findings, magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) analysis, evoked potential testing, and emerging blood-based biomarkers, as no single standalone test definitively confirms the disease. Demand is increasing as healthcare providers emphasize earlier diagnosis to initiate disease-modifying therapies before irreversible neurological damage occurs. Regulatory agencies and neurological societies are continuously updating diagnostic recommendations to incorporate advances in imaging technology, biomarker validation, and artificial intelligence-assisted interpretation that improve clinical decision-making. Strategic investment in precision neurology, digital diagnostics, and minimally invasive biomarker development is strengthening the long-term importance of advanced diagnostic technologies within the global multiple sclerosis care pathway.

Market Drivers

Increasing Prevalence of Multiple Sclerosis

The growing prevalence of multiple sclerosis is increasing demand for accurate and timely diagnostic solutions because earlier disease identification enables prompt initiation of disease-modifying therapies. Delayed diagnosis contributes to irreversible neurological disability as inflammatory disease activity continues before treatment begins. Healthcare providers are expanding utilization of advanced MRI systems, CSF analysis, and multimodal neurological assessments to improve diagnostic confidence. These developments are strengthening demand for comprehensive diagnostic technologies that support long-term disease management.

Growing Adoption of Advanced MRI Technologies

Magnetic resonance imaging remains the cornerstone of multiple sclerosis diagnosis because it enables visualization of demyelinating lesions within the brain and spinal cord. Demand is shifting toward high-field MRI systems and advanced imaging protocols as neurologists require greater sensitivity for detecting early inflammatory changes. Conventional imaging approaches often provide limited lesion characterization in complex cases, encouraging healthcare providers to adopt higher-resolution imaging platforms. Continuous technological innovation is improving diagnostic precision while supporting more standardized neurological assessments.

Rising Demand for Early and Accurate Diagnosis

Earlier diagnosis is becoming increasingly important because disease-modifying therapies provide greater clinical benefit when initiated during the earliest stages of multiple sclerosis. Clinical symptoms frequently overlap with other neurological disorders, creating diagnostic uncertainty that delays treatment decisions. Healthcare organizations are strengthening multidisciplinary diagnostic pathways by integrating imaging findings, laboratory biomarkers, and neurological examinations into comprehensive evaluation protocols. This transition is improving diagnostic confidence while supporting personalized patient management.

Increasing Development of Blood-Based Biomarkers

Research into blood-based biomarkers is expanding because clinicians require minimally invasive diagnostic tools capable of complementing imaging and CSF analysis. Conventional lumbar puncture procedures remain invasive and may reduce patient acceptance during diagnostic evaluation. Diagnostic companies and academic research institutions are developing neurofilament light chain (NfL) assays and additional biomarker technologies that improve disease monitoring and clinical assessment. Continued biomarker validation is strengthening the future role of precision laboratory diagnostics in multiple sclerosis management.

Market Restraints

High cost of advanced MRI systems, specialized laboratory testing, and biomarker-based diagnostics limits widespread adoption across resource-constrained healthcare systems. Absence of a definitive standalone diagnostic test requires integration of multiple clinical and laboratory assessments, increasing diagnostic complexity. Limited availability of specialized neurology centers and trained neuroradiology professionals delays timely diagnosis in several developing healthcare markets. Additionally, variability in reimbursement policies for advanced neuroimaging and biomarker testing can hinder routine clinical adoption.

Technology and Segment Insights

By Diagnostic Modality

Magnetic resonance imaging (MRI) represents the largest diagnostic modality because it remains the primary tool for detecting demyelinating lesions and monitoring disease progression. CSF analysis continues supporting diagnosis when imaging findings require additional clinical confirmation. Blood biomarker tests are gaining increasing attention because they offer minimally invasive disease assessment and facilitate repeated monitoring. Evoked potential tests and optical coherence tomography complement neurological evaluation by detecting functional and structural changes associated with disease progression. Continued integration of multiple diagnostic modalities is strengthening diagnostic accuracy across diverse patient populations.

By Technology

High-field MRI (3T and above) continues gaining clinical preference because improved image resolution enhances lesion visualization and supports earlier diagnosis. Conventional MRI remains widely utilized across routine neurological practice due to broad availability. Artificial intelligence-assisted imaging is improving lesion detection, segmentation, and standardized image interpretation, reducing variability and enhancing workflow efficiency. Immunoassays and molecular diagnostics are becoming increasingly important because biomarker validation continues expanding precision neurology capabilities. The combined adoption of advanced imaging and laboratory technologies is strengthening comprehensive neurological diagnostic pathways.

By End User

Hospitals account for the largest share of diagnostic demand because comprehensive neurological evaluation frequently requires advanced imaging infrastructure, multidisciplinary expertise, and specialized laboratory services. Diagnostic laboratories continue expanding biomarker testing capabilities as precision neurology gains clinical importance. Neurology clinics are increasingly adopting advanced imaging referral pathways and digital diagnostic solutions that improve patient management. Academic and research institutes continue driving biomarker discovery and clinical validation studies supporting future innovation in multiple sclerosis diagnostics.

Competitive and Strategic Outlook

The competitive landscape features major medical technology companies and specialized diagnostic firms. Siemens Healthineers AG differentiates itself through leadership in diagnostic imaging, digital healthcare, and AI-enabled clinical workflow solutions, with a strong portfolio of high-performance MRI systems. GE HealthCare Technologies Inc. maintains a strong position through its broad portfolio of diagnostic imaging systems, digital healthcare solutions, and enterprise imaging platforms. Koninklijke Philips N.V. integrates advanced diagnostic imaging, digital health technologies, and clinical informatics into comprehensive neurological care pathways. Canon Medical Systems Corporation focuses on high-quality imaging performance and clinical innovation in MRI. F. Hoffmann-La Roche Ltd. distinguishes itself through its integrated pharmaceuticals and diagnostics business model, with extensive expertise in molecular and immunodiagnostics. Quest Diagnostics Incorporated leverages one of the largest clinical laboratory networks globally for neurological testing. Thermo Fisher Scientific Inc. provides a broad portfolio spanning molecular biology, analytical instruments, and specialty diagnostics. Abbott Laboratories and Bio-Rad Laboratories contribute through their expertise in immunoassays and molecular diagnostics. QIAGEN N.V. specializes in molecular diagnostics and bioinformatics solutions.
Strategic developments include increasing integration of artificial intelligence into imaging and diagnostic platforms, expansion of blood-based biomarker portfolios, and development of digital neurology solutions. Companies are forming collaborations with healthcare providers, academic institutions, and research organizations to validate emerging technologies and accelerate commercialization. The market is shifting toward integrated diagnostic ecosystems that combine imaging, laboratory testing, and digital health services into unified clinical workflows.

Conclusion

The multiple sclerosis diagnostics market is poised for substantial growth, driven by increasing disease prevalence, technological advancements in MRI and biomarkers, and a growing emphasis on early diagnosis. The shift toward multimodal diagnostic pathways combining high-field imaging, blood-based biomarkers, and AI-assisted interpretation is reshaping clinical practice. Companies that successfully integrate imaging systems, laboratory diagnostics, and digital health platforms into comprehensive precision neurology solutions are expected to strengthen their market position. Ongoing regulatory support, biomarker validation, and expanding healthcare infrastructure across emerging economies will further accelerate innovation and market adoption throughout the forecast period.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Overview
1.2 Market Snapshot
1.3 Key Findings
1.4 Analyst Insights
1.5 Strategic Recommendations

2. Research Methodology

2.1 Research Objectives
2.2 Market Definition
2.3 Research Design
2.4 Data Collection Methodology
2.5 Forecasting Model
2.6 Assumptions and Limitations

3. Market Overview

3.1 Introduction to Multiple Sclerosis Diagnostics
3.2 Evolution of Diagnostic Technologies
3.3 Clinical Diagnosis Workflow
3.4 Diagnostic Ecosystem
3.5 Market Size and Forecast (2026-2035)
3.6 Key Stakeholders

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities

5. Industry Landscape

5.1 Supply Chain Analysis
5.2 Industry Value Chain Analysis
5.3 Pricing Analysis
5.4 Technology Landscape
5.5 Ecosystem Analysis
5.6 Porter's Five Forces Analysis

6. Innovation Landscape

6.1 Artificial Intelligence in MRI Interpretation
6.2 Neurofilament Light Chain (NfL) Biomarker Development
6.3 Digital Neurology Platforms
6.4 Cloud-Based Image Analysis
6.5 Machine Learning in Lesion Detection
6.6 Future Diagnostic Technologies

7. Regulatory Landscape

7.1 United States
7.2 Europe (IVDR)
7.3 Japan
7.4 China
7.5 Australia
7.6 Regulatory Comparison Analysis

8. Market Landscape Analysis

8.1 Competitive Benchmarking
8.2 Company Market Positioning
8.3 Strategic Developments
8.4 Mergers & Acquisitions
8.5 Partnerships & Collaborations
8.6 New Product Launches

9. Market Segmentation

9.1 By Diagnostic Modality
- 9.1.1 Magnetic Resonance Imaging (MRI)
- 9.1.2 Cerebrospinal Fluid (CSF) Analysis (Lumbar Puncture)
- 9.1.3 Blood Biomarker Tests
- 9.1.4 Evoked Potential Tests
- 9.1.5 Optical Coherence Tomography (OCT)
- 9.1.6 Others
9.2 By Technology
- 9.2.1 Conventional MRI
- 9.2.2 High-field MRI (3T & Above)
- 9.2.3 AI-Assisted Imaging
- 9.2.4 Immunoassays
- 9.2.5 Molecular Diagnostics
- 9.2.6 Others
9.3 By End User
- 9.3.1 Hospitals
- 9.3.2 Diagnostic Laboratories
- 9.3.3 Neurology Clinics
- 9.3.4 Academic & Research Institutes

10. Geographic Analysis

10.1 North America
- 10.1.1 United States
- 10.1.2 Canada
- 10.1.3 Mexico
10.2 Europe
- 10.2.1 Germany
- 10.2.2 United Kingdom
- 10.2.3 France
- 10.2.4 Italy
- 10.2.5 Spain
- 10.2.6 Rest of Europe
10.3 Asia Pacific
- 10.3.1 China
- 10.3.2 Japan
- 10.3.3 India
- 10.3.4 South Korea
- 10.3.5 Australia
- 10.3.6 Rest of Asia Pacific
10.4 Latin America
- 10.4.1 Brazil
- 10.4.2 Argentina
- 10.4.3 Rest of Latin America
10.5 Middle East & Africa
- 10.5.1 GCC
- 10.5.2 South Africa
- 10.5.3 Rest of Middle East & Africa